Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$35.52M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
168.55%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$11.46M
Q3 2024
Cash
Q3 2024
P/E
-1.074
Nov 29, 2024 EST
Free Cash Flow
-$29.49M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $295.0K $653.0K $277.0K $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -54.82% 135.74%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $295.0K $653.0K $277.0K $0.00 $0.00 $0.00 $0.00
Cost Of Revenue $790.0K $5.401M $2.249M $0.00 $0.00
Gross Profit -$495.0K -$4.748M -$1.972M $0.00 $0.00
Gross Profit Margin -167.8% -727.11% -711.91%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Selling, General & Admin $11.66M $12.11M $9.820M $15.60M $17.56M $12.45M $27.74M $49.22M $51.59M $26.15M $13.33M $7.210M $1.450M
YoY Change -3.75% 23.35% -37.04% -11.15% 41.02% -55.13% -43.64% -4.6% 97.31% 96.14% 84.91% 397.24%
% of Gross Profit
Research & Development $17.50M $22.53M $17.17M $14.39M $27.84M $14.43M $18.34M $21.64M $18.43M $21.78M $15.80M $6.323M $1.170M
YoY Change -22.32% 31.23% 19.3% -48.32% 93.02% -21.33% -15.27% 17.4% -15.38% 37.86% 149.91% 440.43%
% of Gross Profit
Depreciation & Amortization $381.0K $638.0K $374.0K $339.0K $97.00K $32.00K $1.650M $2.200M $1.300M $450.0K $231.0K $93.00K $0.00
YoY Change -40.28% 70.59% 10.32% 249.48% 203.13% -98.06% -25.0% 69.23% 188.89% 94.81% 148.39%
% of Gross Profit
Operating Expenses $29.16M $22.53M $17.17M $14.39M $27.84M $14.43M $50.90M $81.67M $72.28M $47.93M $29.13M $13.53M $2.620M
YoY Change 29.43% 31.23% 19.3% -48.32% 93.02% -71.66% -37.67% 12.99% 50.79% 64.53% 115.34% 416.37%
Operating Profit -$29.16M -$34.64M -$26.99M -$19.30M -$45.40M -$26.87M -$50.61M -$81.01M -$72.00M -$47.93M -$29.13M -$13.53M
YoY Change -15.83% 28.36% 39.84% -57.49% 68.93% -46.9% -37.53% 12.52% 50.21% 64.53% 115.34%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Interest Expense -$334.0K $1.618M $1.282M $0.00 $1.038M -$134.0K -$266.0K -$883.0K -$1.130M -$1.710M $90.00K $20.00K $0.00
YoY Change -120.64% 26.21% -100.0% -874.63% -49.62% -69.88% -21.86% -33.92% -2000.0% 350.0%
% of Operating Profit
Other Income/Expense, Net -$334.0K -$1.069M -$1.316M $90.00K -$207.0K $40.00K -$36.00K -$164.0K -$20.00K $122.0K $0.00
YoY Change -68.76% -18.77% -1562.22% -143.48% -617.5% -211.11% -78.05% 720.0% -116.39%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Pretax Income -$29.49M -$35.71M -$28.30M -$36.41M -$44.57M -$27.18M -$50.91M -$82.06M -$73.14M -$49.52M -$29.04M -$13.51M -$2.620M
YoY Change -17.41% 26.17% -22.26% -18.31% 63.99% -46.62% -37.96% 12.19% 47.71% 70.5% 114.98% 415.65%
Income Tax $0.00 $0.00 $0.00 $0.00 $67.00K $201.0K $75.00K $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$29.49M -$35.71M -$28.30M -$19.21M -$44.57M -$27.19M -$50.98M -$82.26M -$73.22M -$49.52M -$29.04M -$13.51M -$2.730M
YoY Change -17.41% 26.17% 47.34% -56.9% 63.9% -46.66% -38.03% 12.35% 47.86% 70.5% 114.98% 394.87%
Net Earnings / Revenue -17279.66% -12597.24% -26432.85%
Basic Earnings Per Share -$1.91 -$3.09 -$7.47 -$41.03
Diluted Earnings Per Share -$1.91 -$3.09 -$7.47 -$41.03 -$48.77M -$263.6M -$321.5M -$575.7M -$610.20 -$495.20 -$414.90 -$450.30 -$674.40

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Cash & Short-Term Investments $39.23M $31.23M $51.83M $38.17M $62.48M $77.67M $67.20M $114.4M $126.7M $60.20M $44.40M $31.40M $4.500M
YoY Change 25.62% -39.74% 35.77% -38.9% -19.56% 15.58% -41.25% -9.72% 110.47% 35.59% 41.4% 597.78%
Cash & Equivalents $39.23M $31.23M $51.83M $38.17M $62.48M $73.29M $15.70M $43.93M $43.20M $6.400M $18.10M $14.80M $4.500M
Short-Term Investments $0.00 $4.385M $51.50M $70.46M $83.40M $53.80M $26.30M $16.60M $0.00
Other Short-Term Assets $1.133M $1.720M $17.13M $2.413M $7.378M $3.418M $1.578M $2.056M $3.200M $1.600M $700.0K $600.0K $0.00
YoY Change -34.13% -89.96% 610.07% -67.29% 115.86% 116.6% -23.25% -35.75% 100.0% 128.57% 16.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.36M $32.95M $68.96M $40.90M $71.13M $83.42M $68.78M $116.4M $129.9M $61.90M $45.10M $32.00M $4.600M
YoY Change 22.5% -52.22% 68.61% -42.5% -14.73% 21.29% -40.93% -10.36% 109.85% 37.25% 40.94% 595.65%
Property, Plant & Equipment $10.79M $12.71M $4.164M $2.157M $3.331M $3.113M $5.572M $8.300M $3.400M $900.0K $800.0K $0.00
YoY Change -15.09% 205.24% 93.05% -35.24% -44.13% -32.87% 144.12% 277.78% 12.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $146.0K $65.00K $0.00 $1.500M $0.00
YoY Change 124.62% -100.0%
Other Assets $448.0K $429.0K $111.0K $351.0K $507.0K $652.0K $813.0K $462.0K $400.0K $300.0K $100.0K $100.0K $0.00
YoY Change 4.43% 286.49% -68.38% -30.77% -22.24% -19.8% 75.97% 15.5% 33.33% 200.0% 0.0%
Total Long-Term Assets $11.24M $13.14M $4.275M $2.508M $3.838M $652.0K $4.072M $6.099M $8.700M $3.700M $2.400M $800.0K $0.00
YoY Change -14.45% 207.35% 70.45% -34.65% 488.65% -83.99% -33.23% -29.9% 135.14% 54.17% 200.0%
Total Assets $51.60M $46.09M $73.24M $43.41M $74.97M $84.07M $72.85M $122.5M $138.6M $65.60M $47.50M $32.80M $4.600M
YoY Change
Accounts Payable $845.0K $1.108M $991.0K $1.486M $1.495M $1.998M $2.242M $2.183M $3.400M $2.500M $1.700M $900.0K $300.0K
YoY Change -23.74% 11.81% -33.31% -0.6% -25.18% -10.88% 2.7% -35.79% 36.0% 47.06% 88.89% 200.0%
Accrued Expenses $4.281M $5.719M $4.035M $6.262M $10.82M $7.630M $5.562M $11.03M $7.600M $7.700M $4.100M $1.200M $400.0K
YoY Change -25.14% 41.73% -35.56% -42.11% 41.77% 37.18% -49.56% 45.08% -1.3% 87.8% 241.67% 200.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.285M $239.0K $208.0K $189.0K
YoY Change 14.9% 10.05%
Total Short-Term Liabilities $9.411M $7.277M $20.03M $7.987M $12.52M $9.817M $7.804M $13.21M $11.20M $10.20M $5.800M $2.100M $700.0K
YoY Change 29.33% -63.66% 150.73% -36.21% 27.53% 25.79% -40.92% 17.94% 9.8% 75.86% 176.19% 200.0%
Long-Term Debt $6.264M $10.37M $15.07M $61.00K $168.0K $383.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -39.6% -31.18% 24603.28% -63.69% -56.14%
Other Long-Term Liabilities $9.160M $10.33M $2.026M $1.635M $2.411M $752.0K $751.0K $1.116M $500.0K $100.0K $100.0K $0.00 $100.0K
YoY Change -11.33% 409.87% 23.91% -32.19% 220.61% 0.13% -32.71% 123.2% 400.0% 0.0% -100.0%
Total Long-Term Liabilities $15.42M $20.70M $17.10M $1.696M $2.579M $1.135M $751.0K $1.116M $500.0K $100.0K $100.0K $0.00 $100.0K
YoY Change -25.49% 21.09% 907.96% -34.24% 127.22% 51.13% -32.71% 123.2% 400.0% 0.0% -100.0%
Total Liabilities $24.84M $27.98M $37.12M $10.35M $16.42M $13.12M $8.555M $14.33M $11.80M $10.20M $5.800M $2.100M $800.0K
YoY Change -11.23% -24.63% 258.62% -36.97% 25.15% 53.4% -40.28% 21.4% 15.69% 75.86% 176.19% 162.5%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Basic Shares Outstanding 15.42M 11.55M 3.790M shares 468.2K shares
Diluted Shares Outstanding 15.42M 11.55M 3.790M shares 468.2K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $38.143 Million

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company is headquartered in Brisbane California, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Industry: Pharmaceutical Preparations Peers: ABEONA THERAPEUTICS INC. Aileron Therapeutics, Inc. ATHERSYS, INC / NEW Inhibitor Therapeutics, Inc. Metacrine, Inc. NANOVIRICIDES, INC. ORGANOVO HOLDINGS, INC. KINETA, INC./DE RenovoRx, Inc.